|
Tazorac (tazarotene) Gel approved by the USFDA in June
1997 for the treatment of stable plaque psoriasis of up to 20
% of body surface area.
Metrogel (metronidazole) Gel received USFDA approval
in November 1998 for the treatment of moderate to severe acne
rosacea.
Elidel (pimecrolimus) Cream received USFDA approval in
December 2001 for the treatment of mild to moderate atopic dermatitis
in patients aged 2 years or more.
Botox Cosmetic (botulinum
toxin) was approved by the USFDA
in April 2002 for the temporary improvement of moderate to severe
glabellar wrinkles in adult men and women, ages 65 and younger.
Finacea (azelaic acid) Gel 15% received USFDA approval
in December 2002 for the treatment of mild to moderate acne rosacea.
It is also marketed as Skinoren.
Protopic (tacrolimus) Ointment received USFDA approval
in December 2002 for the treatment of atopic dermatitis in patients
aged 2 years.
Amevive (alefacept) became the first biological therapy
to be approved by the USFDA (in January 2003) for the treatment
of moderate to severe plaque psoriasis. Alefacept works against
psoriasis, in part, by reducing the number of T cells in the
body.
Enbrel (etanercept) received
USFDA approval in April 2004 for chronic moderate to severe psoriasis.
Enbrel inhibits Tumor Necrosis Factor alpha (TNF-alpha), an inflammation-promoting
substance produced by activated T cells in patients with psoriasis.
Radiesse (calcium hydroxylapatite
microspheres) received USFDA approval in December 2006
for facial aesthetic applications. It stimulates the body
to produce new collagen and the improvement is immediate and
lasts an average of one year or more.
Remicade (infliximab) received
USFDA approval in September 2006 for chronic severe plaque psoriasis.
Remicade inhibits Tumor Necrosis Factor alpha (TNF-alpha), an
inflammation-promoting substance produced by activated T cells
in patients with psoriasis.
Humira (adalimumab) received
USFDA approval in January 2008 for treatment of moderate to severe
chronic plaque psoriasis. Humira inhibits Tumor Necrosis Factor
alpha (TNF-alpha), an inflammation-promoting substance produced
by activated T cells in patients with psoriasis.
Raptiva (efalizumab) used for
chronic and severe plaque psoriasis was withdrawn from the US
market as of June 2009 due to increased risk of PML (progressive
multifocal leucoencephalopathy). Raptiva inhibits T cells, the
immune cells that congregate in psoriasis plaques and trigger
inflammation.
Sculptra®Aesthetic (injectable poly-L-lactic
acid) received USFDA approval for for facial aesthetic applications.
Sculptra stimulates the body to produce new collagen. The effect
is gradual and can last up to two years.
Stelara (ustekinumab) received
USFDA approval in September 2009 for the treatment of moderate
to severe plaque psoriasis in adults.Stelera blocks the action
of two cytokines IL-12 and IL-23, which stimulate type 1 T-helper
cell responses and contribute to the overproduction of skin cells
and inflammation.
|
